奇洛斯塔在治疗间歇性听症方面具有有益作用:来自多中心,随机,前性,双盲试验的结果
D L Dawson1, B S Cutler, M H Meissner
1Department of Surgery, University of Washington, Seattle, USA. dawson@whmc.af.mil
奇洛斯塔显著改善了间歇性关患者的步行距离. 这种固酶抑制剂是安全的,耐受性很好,增强了初始和绝对的缩距离.
科学领域:
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奇洛斯塔是一种固酶抑制剂,具有抗血小板和血管扩张的特性.
- 间歇性音是外周动脉疾病的常见症状.
研究的目的:
- 评估基洛斯塔在治疗稳定,中度严重间歇性硬的疗效和安全性.
- 评估基洛斯塔对步行距离和患者报告结果的影响.
主要方法:
- 潜在的,随机的,安慰剂控制的,并行组临床试验.
- 在81名间歇性的受试者中,随机分配给12周的西洛斯塔 (100毫克两次) 或安慰剂.
- 主要结局:初始音距离 (ICD) 和绝对音距离 (ACD) 通过跑步机测试测量.
主要成果:
- 基洛斯塔治疗导致ICD增加了35% (P<0.01) 和ACD增加了41% (P<0.01).
- 没有观察到足/手臂指数的显著变化.
- 患者和医生的主观评估证实了步行表现的改善.
结论:
- 奇洛斯塔可显著改善间歇性关患者的步行距离.
- 奇洛斯塔在这种适应症中表现出良好的安全性和耐受性.
更多相关视频
14:52Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
Published on: December 11, 2013
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Treatment of Constipation-Predominant IBS
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management
